215 related articles for article (PubMed ID: 25759146)
1. Circulating angiogenic factors associated with response and survival in patients with acute graft-versus-host disease: results from Blood and Marrow Transplant Clinical Trials Network 0302 and 0802.
Holtan SG; Verneris MR; Schultz KR; Newell LF; Meyers G; He F; DeFor TE; Vercellotti GM; Slungaard A; MacMillan ML; Cooley SA; Blazar BR; Panoskaltsis-Mortari A; Weisdorf DJ
Biol Blood Marrow Transplant; 2015 Jun; 21(6):1029-36. PubMed ID: 25759146
[TBL] [Abstract][Full Text] [Related]
2. Follistatin and Soluble Endoglin Predict 1-Year Nonrelapse Mortality after Allogeneic Hematopoietic Cell Transplantation.
Newell LF; DeFor TE; Cutler C; Verneris MR; Blazar BR; Miller JS; Antin JH; Howard A; Wu J; MacMillan ML; Panoskaltsis-Mortari A; Weisdorf DJ; Holtan SG
Biol Blood Marrow Transplant; 2020 Mar; 26(3):606-611. PubMed ID: 31715306
[TBL] [Abstract][Full Text] [Related]
3. Serum albumin level predicts survival of patients with gastrointestinal acute graft-versus-host disease after allogeneic stem cell transplantation.
Ayuk F; Bussmann L; Zabelina T; Veit R; Alchalby H; Wolschke C; Lellek H; Bacher U; Zander AR; Kröger N
Ann Hematol; 2014 May; 93(5):855-61. PubMed ID: 24248672
[TBL] [Abstract][Full Text] [Related]
4. Angiogenic factors are associated with development of acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
Nie DM; Wu QL; Zhu XX; Zhang R; Zheng P; Fang J; You Y; Zhong ZD; Xia LH; Hong M
J Huazhong Univ Sci Technolog Med Sci; 2015 Oct; 35(5):694-699. PubMed ID: 26489624
[TBL] [Abstract][Full Text] [Related]
5. Plasma microRNA signature as a noninvasive biomarker for acute graft-versus-host disease.
Xiao B; Wang Y; Li W; Baker M; Guo J; Corbet K; Tsalik EL; Li QJ; Palmer SM; Woods CW; Li Z; Chao NJ; He YW
Blood; 2013 Nov; 122(19):3365-75. PubMed ID: 24041574
[TBL] [Abstract][Full Text] [Related]
6. Late Acute Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation.
Omer AK; Weisdorf DJ; Lazaryan A; Shanley R; Blazar BR; MacMillan ML; Brunstein C; Bejanyan N; Arora M
Biol Blood Marrow Transplant; 2016 May; 22(5):879-83. PubMed ID: 26743342
[TBL] [Abstract][Full Text] [Related]
7. Higher angiopoietin-2 and VEGF levels predict shorter EFS and increased non-relapse mortality after pediatric hematopoietic SCT.
Porkholm M; Bono P; Saarinen-Pihkala UM; Kivivuori SM
Bone Marrow Transplant; 2013 Jan; 48(1):50-5. PubMed ID: 22659681
[TBL] [Abstract][Full Text] [Related]
8. High day 28 ST2 levels predict for acute graft-versus-host disease and transplant-related mortality after cord blood transplantation.
Ponce DM; Hilden P; Mumaw C; Devlin SM; Lubin M; Giralt S; Goldberg JD; Hanash A; Hsu K; Jenq R; Perales MA; Sauter C; van den Brink MR; Young JW; Brentjens R; Kernan NA; Prockop SE; O'Reilly RJ; Scaradavou A; Paczesny S; Barker JN
Blood; 2015 Jan; 125(1):199-205. PubMed ID: 25377785
[TBL] [Abstract][Full Text] [Related]
9. Low Counts of Plasmacytoid Dendritic Cells after Engraftment Are Associated with High Early Mortality after Allogeneic Stem Cell Transplantation.
Gonçalves MV; Yamamoto M; Kimura EY; Colturato VA; de Souza MP; Mauad M; Ikoma MV; Novis Y; Rocha V; Ginani VC; Wanderley de Oliveira Felix OM; Seber A; Kerbauy FR; Hamerschlak N; Orfao A; Rodrigues CA
Biol Blood Marrow Transplant; 2015 Jul; 21(7):1223-9. PubMed ID: 25792371
[TBL] [Abstract][Full Text] [Related]
10. Increased Galectin-9 expression, a prognostic biomarker of aGVHD, regulates the immune response through the Galectin-9 induced MDSC pathway after allogeneic hematopoietic stem cell transplantation.
Yin J; Li L; Wang C; Zhang Y
Int Immunopharmacol; 2020 Nov; 88():106929. PubMed ID: 32889240
[TBL] [Abstract][Full Text] [Related]
11. Associations between acute GVHD-related biomarkers and endothelial cell activation after allogeneic hematopoietic stem cell transplantation.
Nomura S; Ishii K; Fujita S; Nakaya A; Satake A; Ito T
Transpl Immunol; 2017 Aug; 43-44():27-32. PubMed ID: 28687251
[TBL] [Abstract][Full Text] [Related]
12. Influence of post-transplant mucosal-associated invariant T cell recovery on the development of acute graft-versus-host disease in allogeneic bone marrow transplantation.
Kawaguchi K; Umeda K; Hiejima E; Iwai A; Mikami M; Nodomi S; Saida S; Kato I; Hiramatsu H; Yasumi T; Nishikomori R; Kondo T; Takaori-Kondo A; Heike T; Adachi S
Int J Hematol; 2018 Jul; 108(1):66-75. PubMed ID: 29582333
[TBL] [Abstract][Full Text] [Related]
13. Immunomodulation effects of mesenchymal stromal cells on acute graft-versus-host disease after hematopoietic stem cell transplantation.
Zhao K; Lou R; Huang F; Peng Y; Jiang Z; Huang K; Wu X; Zhang Y; Fan Z; Zhou H; Liu C; Xiao Y; Sun J; Li Y; Xiang P; Liu Q
Biol Blood Marrow Transplant; 2015 Jan; 21(1):97-104. PubMed ID: 25300866
[TBL] [Abstract][Full Text] [Related]
14. Association of Pre-Transplant Angiopoietin-2 Index with the Risk of Acute Graft-Versus-Host Disease after Hematopoietic Stem Cell Transplantation.
Satırer Ö; Cevher Zeytin İ; Alkan B; Karakaya J; Çetinkaya D; Visal Okur F
Turk J Haematol; 2022 Feb; 39(1):61-65. PubMed ID: 34617432
[TBL] [Abstract][Full Text] [Related]
15. Treatment of Acute Graft-versus-Host Disease in Childhood with Extracorporeal Photochemotherapy/Photopheresis: The Padova Experience.
Calore E; Marson P; Pillon M; Tumino M; Tison T; Mainardi C; De Silvestro G; Rossin S; Franceschetto G; Carraro E; Pescarin M; Varotto S; Destro R; Gazzola MV; Basso G; Messina C
Biol Blood Marrow Transplant; 2015 Nov; 21(11):1963-72. PubMed ID: 26183078
[TBL] [Abstract][Full Text] [Related]
16. Soluble interleukin-2 receptor concentration as a biochemical indicator for acute graft-versus-host disease after allogeneic bone marrow transplantation.
Mathias C; Mick R; Grupp S; Duffy K; Harris F; Laport G; Stadtmauer E; Luger S; Schuster S; Wasik MA; Porter DL
J Hematother Stem Cell Res; 2000 Jun; 9(3):393-400. PubMed ID: 10894361
[TBL] [Abstract][Full Text] [Related]
17. Tocilizumab as first-line therapy for steroid-refractory acute graft-versus-host-disease: analysis of a single-center experience.
Yucebay F; Matthews C; Puto M; Li J; William B; Jaglowski SM; Penza SL; Vasu S; Benson DM; Andritsos LA; Devine SM; Efebera YA; Roddy JVF
Leuk Lymphoma; 2019 Sep; 60(9):2223-2229. PubMed ID: 30764681
[TBL] [Abstract][Full Text] [Related]
18. Effect of Sirolimus on Immune Reconstitution Following Myeloablative Allogeneic Stem Cell Transplantation: An Ancillary Analysis of a Randomized Controlled Trial Comparing Tacrolimus/Sirolimus and Tacrolimus/Methotrexate (Blood and Marrow Transplant Clinical Trials Network/BMT CTN 0402).
Gooptu M; Kim HT; Howard A; Choi SW; Soiffer RJ; Antin JH; Ritz J; Cutler CS
Biol Blood Marrow Transplant; 2019 Nov; 25(11):2143-2151. PubMed ID: 31271885
[TBL] [Abstract][Full Text] [Related]
19. Low EGF in myeloablative allotransplantation: association with severe acute GvHD in BMT CTN 0402.
Holtan SG; Newell LF; Cutler C; Verneris MR; DeFor TE; Wu J; Howard A; MacMillan ML; Antin JH; Blazar BR; Weisdorf DJ; Panoskaltsis-Mortari A
Bone Marrow Transplant; 2017 Sep; 52(9):1300-1303. PubMed ID: 28581470
[TBL] [Abstract][Full Text] [Related]
20. Grade II Acute Graft-versus-Host Disease and Higher Nucleated Cell Graft Dose Improve Progression-Free Survival after HLA-Haploidentical Transplant with Post-Transplant Cyclophosphamide.
McCurdy SR; Kanakry CG; Tsai HL; Kasamon YL; Showel MM; Bolaños-Meade J; Huff CA; Borrello I; Matsui WH; Brodsky RA; Ambinder RF; Bettinotti MP; Fuchs EJ; Rosner GL; Jones RJ; Luznik L
Biol Blood Marrow Transplant; 2018 Feb; 24(2):343-352. PubMed ID: 29055682
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
